Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 328

Similar articles for PubMed (Select 17502726)

1.

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.

Seyler C, Adjé-Touré C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, Nolan M, Toure S, Anglaret X.

AIDS. 2007 May 31;21(9):1157-64.

2.

Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S49-54.

PMID:
14565609
3.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
4.
5.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
6.

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.

PMID:
14565604
7.
9.

Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, Fassinou P, Bissagnene E, Kadio A, Nolan ML, Nkengasong JN.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):911-7. doi: 10.1089/aid.2007.0264.

PMID:
18593341
10.

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.

AIDS. 2006 Aug 1;20(12):1613-9. Erratum in: AIDS. 2006 Aug 22;20(13):1790.

PMID:
16868442
11.

Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.

Uy J, Armon C, Buchacz K, Wood K, Brooks JT; HOPS Investigators.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):450-3. doi: 10.1097/QAI.0b013e3181acb630.

PMID:
19474757
12.

Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.

Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD.

Scand J Infect Dis. 2005;37(11-12):890-901.

PMID:
16308226
13.

Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.

Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE.

AIDS Patient Care STDS. 2007 Aug;21(8):544-50.

PMID:
17711379
14.

Medium-term probability of success of antiretroviral treatment after early warning signs of treatment failure in West African adults.

Danel C, Gabillard D, Inwoley A, Chaix ML, Toni TD, Moh R, Messou E, Bissagnene E, Salamon R, Eholie S, Anglaret X.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):783-93. doi: 10.1089/aid.2009.0018.

PMID:
19619008
15.

HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.

Hanson DL, Adjé-Touré C, Talla-Nzussouo N, Eby P, Borget MY, Kouadio LY, Celestin BE, Tossou O, Eholie S, Kadio A, Chorba T, Nkengasong JN.

AIDS Res Hum Retroviruses. 2009 May;25(5):489-95. doi: 10.1089/aid.2008.0273.

PMID:
19388820
16.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
17.

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A.

AIDS. 2002 Feb 15;16(3):369-79.

PMID:
11834948
18.

Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.

Al Mazari A, Zomaya AY, Charleston M, Salem H, Maher A, Garsia RJ.

Curr HIV Res. 2007 Jul;5(4):430-9.

PMID:
17627506
19.

High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.

Sung H, Jung YS, Kang MW, Bae IG, Chang HH, Woo JH, Cho YK.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1223-9.

PMID:
17961108
20.

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.

PMID:
17146376
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk